Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy  Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman - PR Newswire

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman  PR Newswire

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman - PR Newswire

Click here to get full coverage on UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT  GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Click here to get full coverage on Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking  simplywall.st

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Click here to get full coverage on New Analyst Forecast: $URGN Given $16.0 Price Target - Nasdaq

New Analyst Forecast: $URGN Given $16.0 Price Target  Nasdaq

New Analyst Forecast: $URGN Given $16.0 Price Target - Nasdaq

Click here to get full coverage on HC Wainwright & Co. Reiterates Buy Rating on URGN with $50 Target | URGN Stock News - GuruFocus

HC Wainwright & Co. Reiterates Buy Rating on URGN with $50 Target | URGN Stock News  GuruFocus

HC Wainwright & Co. Reiterates Buy Rating on URGN with $50 Target | URGN Stock News - GuruFocus

Click here to get full coverage on Trading (URGN) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (URGN) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (URGN) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN - Morningstar

Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN  Morningstar

Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN - Morningstar

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

Click here to get full coverage on URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. - GlobeNewswire

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd.  GlobeNewswire

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. - GlobeNewswire

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman  PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

Click here to get full coverage on Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or  GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Click here to get full coverage on URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit  PR Newswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Click here to get full coverage on URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit  PR Newswire

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Click here to get full coverage on What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You  富途牛牛

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

Click here to get full coverage on URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63 - simplywall.st

Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63  simplywall.st

Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63 - simplywall.st

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

Click here to get full coverage on URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News  GuruFocus

URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ)  Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors  GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire

Click here to get full coverage on Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan

Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment  Stock Titan

Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN): Navigating Regulatory Crossroads and Strategic Reassessment - AInvest

UroGen Pharma (URGN): Navigating Regulatory Crossroads and Strategic Reassessment  AInvest

UroGen Pharma (URGN): Navigating Regulatory Crossroads and Strategic Reassessment - AInvest

Click here to get full coverage on Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire

Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith  Business Wire

Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire

Click here to get full coverage on UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

Click here to get full coverage on URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with - GlobeNewswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with  GlobeNewswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with - GlobeNewswire

Click here to get full coverage on Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News  GuruFocus

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus

Click here to get full coverage on The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN - GlobeNewswire

The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN  GlobeNewswire

The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN - GlobeNewswire

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - PR Newswire

Click here to get full coverage on URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire

URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors  Business Wire

URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire

Click here to get full coverage on URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Morningstar

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit  Morningstar

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Morningstar

Click here to get full coverage on UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen Pharma (URGN) Soars as FDA Decision Nears - GuruFocus

UroGen Pharma (URGN) Soars as FDA Decision Nears  GuruFocus

UroGen Pharma (URGN) Soars as FDA Decision Nears - GuruFocus

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on UroGen Pharma (URGN) Faces Close Vote on UGN-102 by FDA Advisory Committee | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Faces Close Vote on UGN-102 by FDA Advisory Committee | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Faces Close Vote on UGN-102 by FDA Advisory Committee | URGN Stock News - GuruFocus

Click here to get full coverage on Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm  GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - GlobeNewswire

Click here to get full coverage on Shareholders that lost money on UroGen Pharma Ltd. (URGN) - GlobeNewswire

Shareholders that lost money on UroGen Pharma Ltd. (URGN)  GlobeNewswire

Shareholders that lost money on UroGen Pharma Ltd. (URGN) - GlobeNewswire

Click here to get full coverage on Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)  富途牛牛

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛

Click here to get full coverage on Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma (NASDAQ:URGN) - Benzinga

Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma (NASDAQ:URGN)  Benzinga

Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma (NASDAQ:URGN) - Benzinga

Click here to get full coverage on UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either (URGN) - Seeking Alpha

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either (URGN)  Seeking Alpha

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either (URGN) - Seeking Alpha

Click here to get full coverage on FDA Greenlights UroGen Pharma's ZUSDURI for Recurrent Bladder Cancer Treatment | URGN Stock News - GuruFocus

FDA Greenlights UroGen Pharma's ZUSDURI for Recurrent Bladder Cancer Treatment | URGN Stock News  GuruFocus

FDA Greenlights UroGen Pharma's ZUSDURI for Recurrent Bladder Cancer Treatment | URGN Stock News - GuruFocus

Click here to get full coverage on URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com - Financial Times

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com  Financial Times

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com - Financial Times

Click here to get full coverage on UroGen Pharma (URGN) Soars After FDA Approval and Price Target Boost - GuruFocus

UroGen Pharma (URGN) Soars After FDA Approval and Price Target Boost  GuruFocus

UroGen Pharma (URGN) Soars After FDA Approval and Price Target Boost - GuruFocus

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC - Insider Monkey

UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC  Insider Monkey

UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC - Insider Monkey

Click here to get full coverage on UroGen Pharma (URGN) Downgraded by HC Wainwright & Co. | URGN St - GuruFocus

UroGen Pharma (URGN) Downgraded by HC Wainwright & Co. | URGN St  GuruFocus

UroGen Pharma (URGN) Downgraded by HC Wainwright & Co. | URGN St - GuruFocus

Click here to get full coverage on URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com - Financial Times

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com  Financial Times

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company Announcement - FT.com - Financial Times

Click here to get full coverage on DEADLINE ALERT for DV, OGN, RCAT, and URGN: The Law Offices - GlobeNewswire

DEADLINE ALERT for DV, OGN, RCAT, and URGN: The Law Offices  GlobeNewswire

DEADLINE ALERT for DV, OGN, RCAT, and URGN: The Law Offices - GlobeNewswire

Click here to get full coverage on What's Going On With UroGen Pharma Stock Wednesday? - Benzinga

What's Going On With UroGen Pharma Stock Wednesday?  Benzinga

What's Going On With UroGen Pharma Stock Wednesday? - Benzinga

Click here to get full coverage on URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC  GlobeNewswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Click here to get full coverage on UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Yahoo Finance

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update  Yahoo Finance

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Yahoo Finance

Click here to get full coverage on URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff ... - Bluefield Daily Telegraph

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff ...  Bluefield Daily Telegraph

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff ... - Bluefield Daily Telegraph

Click here to get full coverage on Urogen Pharma’s chief medical officer sells $38,043 in shares - Investing.com

Urogen Pharma’s chief medical officer sells $38,043 in shares  Investing.com

UroGen Pharma Ltd (URGN)

Price Chart

Key Statistics

Technicals

About URGN

Latest News

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman - PR Newswire

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Advanced Charts

Top Gainers

Top Losers